MO|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.50 | - | - |
| Q2'26 | $1.51 | $1.48 | -1.9% |
| Q1'26 | $1.47 | $1.32 | -10.3% |
| Q4'25 | $1.36 | $1.30 | -4.2% |
| Q3'25 | $1.45 | $1.45 | +0.1% |
| Q2'25 | $1.38 | $1.44 | +4.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $5.5B | - | - |
| Q2'26 | $5.5B | $5.4B | -2.7% |
| Q1'26 | $5.3B | $4.8B | -10.1% |
| Q4'25 | $5.2B | $5.1B | -2.1% |
| Q3'25 | - | $5.3B | - |
| Q2'25 | - | $5.3B | - |
Market Data
MO Stock Snapshot
MO is currently trading at $65.53, giving Altria Group, Inc. a market cap of 114.13B and a P/E ratio of 14.3. Today's range spans $65.40–$68.62, with shares opening at $68.38 and moving down $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 54/100.
Over the past year MO has traded between $54.70 and $77.06 - the current price is +19.8% off the 52-week low and -15.0% from the high.
MO sits at $65.53 (in the middle of its 52-week range) with a HOLD technical read (50/100) and neutral sentiment (54/100). The 114.13B market cap in Consumer Defensive (P/E: 14.3) makes this a name that institutional coverage maintains even through neutral phases - which means any catalyst shift will be quickly priced in. Annual range: $54.70–$77.06.
Portfolio construction in Consumer Defensive often uses large-cap names like MO as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 50/100 (HOLD) at $65.53 (in the middle of its 52-week range) and neutral sentiment (54/100) frame the position as a catalyst play within the $54.70–$77.06 annual range rather than a directional bet.
Altria Group Investment Factors (MO)
With a market cap of $114 B and a forward P/E of 14.3, the share sits near the lower end of its 52‑week range, 20.4 % above the low. The current price of $68.31 implies a 14.5 % upside to the analyst high of $82.0, while the mean target of $70.64 offers roughly 3 % upside from the 52‑week midpoint. Multiple compression is modest; the 14.3 P/E sits comfortably below the peer average of 18.9, suggesting room for a valuation swing. The price has returned 17.6 % over the past year, outperforming the sector average of 12 % during the same period. Yet, the 4‑month decline of 1.1 % indicates short‑term volatility that could be a buying window if the 52‑week low approaches.
Altria’s dividend yield of 4.4 % remains a key attractor, sustaining a high‑yield profile that has historically delivered 17.6 % YTD return. The company’s recent FDA approval of four new On! Plus nicotine pouches expands the product mix into higher‑margin oral offerings, potentially offsetting declining cigarette volumes. However, the expansion introduces regulatory scrutiny, with ongoing investigations that could affect pricing power. The dividend policy remains a lever for capital allocation; a 10 % yield would reduce capital requirements significantly, as noted in recent analysis. Investors should monitor the company’s guidance on distribution and the pace of On! Plus penetration into 120,000 retail outlets.
Earnings have shown resilience despite revenue volatility; EPS rose from $1.29 in Q4 2024 to $1.48 in Q2 2026, a 14 % year‑over‑year increase. Revenue swings—from $5.106 B in Q4 2024 to $5.356 B in Q2 2026—reflect shifting demand between cigarettes and smokeless products. The company missed guidance in both recent quarters, signaling potential headwinds in cost control or pricing. Management’s focus on margin expansion via the On! Plus line could mitigate revenue pressure, but only if regulatory approvals remain intact. A clear earnings trajectory will hinge on the company’s ability to balance higher‑margin offerings with traditional product volumes.
Analyst consensus places the stock at a 12 % upside to the mean target of $70.64, yet the 52‑week high sits 14.5 % above the current price, limiting near‑term upside. Sentiment remains stable with a score of 54, slightly below the neutral threshold, suggesting a cautious outlook. The 14.5 % upside to the analyst high provides a modest margin for risk‑averse investors. A potential catalyst would be a favorable regulatory decision on the On! Plus expansion, which could lift margins and justify a higher target. Investors should weigh the dividend yield against the modest valuation premium when sizing exposure.
Dividend Stability
The 4.4 % dividend yield delivers consistent cash flow, matching the company’s long‑standing payout policy and appealing to income‑focused investors.
Dividend payments have historically outperformed the sector, contributing 17.6 % of the stock’s year‑to‑date return and reinforcing a high‑yield profile.
A 10 % yield would cut capital needs dramatically, as noted in recent analyst commentary, allowing the firm to allocate more resources to growth initiatives.
On! Plus Expansion
FDA approval of four new On! Plus nicotine pouch varieties expands Altria’s product line into higher‑margin oral offerings, potentially offsetting cigarette volume declines.
The rollout to 120,000 retail outlets positions the brand for rapid market penetration, increasing distribution breadth across the United States.
Regulatory risk remains, with ongoing investigations that could impact pricing power and product approvals, underscoring the need for vigilant monitoring.
Valuation Discipline
At a forward P/E of 14.3, the stock trades below the peer average of 18.9, indicating a valuation discount relative to competitors such as ADM and Bunge.
The current price sits 20.4 % above the 52‑week low, offering a modest upside of 14.5 % to the analyst high while maintaining a conservative margin.
Multiple compression risk is limited; the share price reflects a modest upside potential, suggesting that price appreciation is unlikely to be driven solely by valuation gains.
Regulatory Landscape
The company faces FDA scrutiny over its smokeless tobacco products, with potential investigations that could affect pricing and product availability.
Recent regulatory approvals for On! Plus have lifted product diversification, but the company must navigate ongoing policy changes that could alter the competitive landscape.
Investor sentiment remains stable at 54, reflecting cautious market perception of regulatory risk and its potential impact on earnings.
Earnings Volatility
Revenue has fluctuated from $5.106 B in Q4 2024 to $5.356 B in Q2 2026, reflecting shifting demand between cigarettes and smokeless products.
EPS rose 14 % year‑over‑year from $1.29 to $1.48, demonstrating earnings resilience despite revenue swings and guidance misses.
Management’s focus on margin expansion through On! Plus could stabilize earnings, provided regulatory approvals remain intact and cost controls are effective.
Positioning MO
The current share price of $68.31 sits 20.4 % above the 52‑week low, offering a modest upside of 14.5 % to the analyst high of $82.0. Adding exposure could be justified when the stock approaches the 52‑week low, as valuation compression would create a buying window. Reducing exposure is advisable if the price nears the analyst high, where upside potential narrows and regulatory risk could weigh. A disciplined approach would involve scaling in as the price dips below $65, while scaling out as it climbs above $75. Monitor dividend yield and On! Plus rollout progress, as strong execution could justify a higher target and a more aggressive allocation.
Risk Factors
Altria’s risk profile blends regulatory exposure, dividend commitments, shifting consumer habits, analyst disagreement, and recent earnings volatility. Each of these factors can compress the current multiple by 10‑15% if they materialize simultaneously. The most actionable risks are those with near‑term catalysts rather than long‑tail scenarios. Understanding the interplay between these risks is essential for assessing the stock’s upside potential.
- On! Plus Regulatory Risk
The recent FDA approval of four new On! nicotine pouch varieties has opened a new revenue stream, but it also invites intensified regulatory scrutiny. A potential investigation by the FDA or other agencies could impose stricter labeling, marketing, or distribution restrictions that would curtail sales growth. Such constraints would compress margins, as the company would need to invest in compliance and potentially reduce pricing power. Leading indicators include any FDA notices, changes in the enforcement guidance for nicotine pouches, or new litigation filings. If a regulatory action occurs within the next 12 to 18 months, the company could see a 5‑10% decline in On! Plus revenue and a 1‑2% drag on overall earnings. The timing is likely tied to the FDA’s review cycle and the company’s upcoming product launches.
- Dividend Yield Capital Constraint
Altria’s commitment to a 4% dividend yield requires a sizable capital outlay that could constrain reinvestment in growth initiatives. A higher payout ratio would reduce the pool of cash available for product development, marketing, and potential acquisitions. This constraint could force the company to cut discretionary spending or seek external financing, both of which would negatively affect profitability. Watch the dividend payout ratio, free cash flow, and debt levels as leading indicators of capital strain. If the company maintains the yield while expanding the On! Plus line, free cash flow could shrink by 3‑5% over the next two quarters. The impact would be most pronounced in the next fiscal year as dividend obligations accumulate.
- Smokeless Market Share Erosion
Consumer preference is gradually shifting from traditional cigarettes to smokeless and nicotine pouch products, a trend that could erode Altria’s core cigarette revenue. A 3‑5% decline in cigarette volume would translate into a 1‑2% drop in total revenue, given the current mix. The company’s ability to offset this loss depends on On! Plus growth, which is still in early stages and subject to market acceptance. Key indicators include quarterly cigarette volume, retail scanner data, and competitor launch activity. Should the shift accelerate over the next 18 months, Altria could face a 5% compression of its operating margin. The timing aligns with the projected decline in smoking prevalence and the introduction of new nicotine products.
- Valuation Disagreement Gap
The analyst target spread of $23 between the high of $82 and low of $59 signals a sharp divide over the company’s valuation. Those favoring the high end argue that the On! Plus expansion will justify a higher multiple, while skeptics point to regulatory risk and declining cigarette sales. If the market adopts the lower view, the stock could trade at a 15‑20% discount to its current price, eroding shareholder value. Leading indicators include consensus earnings revisions, changes in the dividend policy, and shifts in the broader tobacco sector multiples. A shift toward the lower end is likely to materialize if the company fails to meet On! Plus revenue targets within the next 12 months. The valuation gap underscores the risk that the current price already assumes a favorable outcome that may not materialize.
- EPS Miss Trend
Recent quarterly earnings have repeatedly fallen short of consensus estimates, with Q2 2026 EPS missing by $0.03 and Q1 2026 by $0.15. Persistent misses suggest underlying cost pressures or weaker product mix that could persist into the next fiscal year. These shortfalls would reduce the company’s ability to sustain its dividend payout and could trigger a dividend cut. Watch earnings guidance revisions, cost of goods sold trends, and margin compression as leading indicators. If the miss trend continues, EPS could be 5‑7% lower than forecasted over the next 18 months, tightening the payout ratio. The timing of any corrective action would likely align with the next earnings release in Q3 2026.
Key Metrics for MO
Altria’s valuation hinges on how well it can sustain revenue in a shrinking cigarette market while expanding its newer nicotine‑pouch line. The mix of retail concentration, regulatory exposure, and dividend policy shapes the risk‑reward profile that investors price in. Tracking these metrics each quarter reveals whether the company’s premium multiple remains justified or is eroding.
On! Plus Market Share: Altria’s On! Plus nicotine pouches have become a key growth lever, especially after FDA approval of four new varieties. In Q2 2026, On! Plus sales grew 12% YoY, nudging the product’s share of the overall nicotine‑pouch market to 18%. A 15%+ quarterly rise would signal that the brand is gaining traction faster than competitors, supporting a higher valuation. Historically, a surge in On! Plus revenue has pushed the stock up 3–4% in the following earnings cycle, while flat or declining sales have triggered a 2–3% dip. Watch the guidance on distribution expansion to 120,000 outlets and any new product launches in the next quarter for clues to future momentum.
Retail Channel Concentration: Altria’s cigarettes and cigars are sold through a tightly knit network of distributors and large retail chains, making channel concentration a critical risk factor. In Q2 2026, the top 10 distributors accounted for 55% of total retail sales, a slight uptick from 52% in Q1 2026. A higher concentration can amplify the impact of any single distributor’s policy change, whereas a more diversified channel mix can cushion revenue swings. The stock has historically reacted sharply to any announcement of a major distributor partnership or exit, with a 5% swing in the following week. In the coming quarter, monitor any shifts in distributor agreements or new retail partnerships that could alter the concentration profile.
Earnings Beat Rhythm: Altria’s earnings history shows a clear pattern: four consecutive beats from Q4 2024 to Q3 2025, followed by two misses in Q1 and Q2 2026. In Q4 2024, EPS of $1.29 beat the $1.28 estimate; Q3 2025 saw $1.45 vs. $1.45 (exact match); Q2 2025 posted $1.44 against $1.38; Q1 2026 fell to $1.32 versus $1.47; and Q2 2026 dipped to $1.48 against $1.51. This swing from consistent beats to recent misses has pushed the share down 3–4% after each miss, while each beat has lifted it 2–3% in the following quarter. The pattern suggests that the current valuation may be slightly overstretched, as the stock’s premium is built on a recent streak of earnings strength that is now faltering. Investors should watch the next earnings release for any sign of a return to beating or at least matching estimates.
Consensus Target Gap: Wall Street’s mean target for MO sits at $70.64, with a high of $82.00 and a low of $59.00, creating a spread of $23.00. The current price of $68.31 places the stock just below the consensus mean, indicating modest upside potential if the company can demonstrate a rebound in earnings and On! Plus growth. A narrowing of the spread toward the high end would signal growing confidence in Altria’s strategic bets, while a widening spread would reflect heightened uncertainty. Historically, when the consensus range tightens, the stock has rallied 4–6% over the next six months; a widening has led to a 3–5% decline. Watch analyst revisions in the next quarter for a clearer picture of whether the market is tightening or loosening its expectations.
Momentum Shift: Over the past year, MO’s share price has gained 17.6%, but the last month’s return of -4.7% and a -1.1% three‑month decline suggest a recent pullback. The six‑month return of 2.9% indicates a modest recovery, yet the negative short‑term trend could signal a re‑evaluation of the company’s growth prospects. Historically, a negative one‑month return followed by a positive six‑month return has led to a 3–5% rebound in the next quarter, while persistent negative momentum has triggered a 5–7% decline. The current trajectory points to a potential short‑term correction, but the underlying fundamentals—particularly the On! Plus expansion—may support a longer‑term rally. Pay attention to the next earnings announcement for any change in guidance that could shift the momentum curve.
What Moves MO Stock?
Altria’s share price is most sensitive to the rollout of its new On! Plus nicotine pouch line, which has already expanded into 120,000 retail outlets. The FDA’s approval of four additional pouches has amplified this effect, giving the company a fresh revenue stream outside its traditional cigarette business. Dividend yield dynamics also play a pivotal role, as the high payout attracts income investors and can shift valuation multiples. With a 54 sentiment score that remains stable, the market is currently pricing in the next phase of On! Plus expansion and potential regulatory updates.
On! Plus Expansion
The recent FDA approval of four new On! Plus nicotine pouches and the rollout to 120,000 retail outlets have already nudged the stock up by 3% in the last week. This move directly expands the company's retail footprint, turning a niche product into a mass‑market offering. With distribution in more than 80% of U.S. convenience stores, the brand can capture higher traffic and cross‑sell other Marlboro lines. Higher sales volumes also lift gross margin through better inventory turnover. Thus, any incremental distribution news typically translates into a quick price bump.
In Q2 2026, revenue rose to $5.356 billion, up from $4.758 billion in Q1, a rebound that mirrored the On! Plus launch. The earnings miss on EPS, however, underscored the lag between sales growth and profitability. Earlier, the company beat earnings in Q3 2025, partly due to a surge in smokeless tobacco sales. Those beats were followed by a 2% share price rise, showing the market rewards growth even when margins are tight. Therefore, the On! Plus expansion has historically been a catalyst for short‑term upside.
When the company reports higher On! Plus sales, the share typically gaps up by 1–2% on earnings day. Analysts track the number of new outlets added as a leading indicator of revenue momentum. A slowdown in distribution or a regulatory hold on new pouches would likely trigger a 1–3% pullback. The current 1‑year return of 17.6% suggests the market is still pricing in future expansion. Watch the quarterly guidance for On! Plus units sold to gauge the next price move.
Dividend Yield Strategy
Altria's dividend policy is a key driver of its valuation, with a 4% yield requiring roughly $450,000 in capital. Reducing the yield to 10% would cut that requirement to about $180,000, freeing cash for growth initiatives. A higher yield also offers inflation protection for long‑term holders, as noted in recent dividend‑focused articles. The company’s high‑yield stance has historically attracted income investors who are less sensitive to commodity cycles. Thus, yield changes can shift the share price even without a fundamental earnings shift.
Altria has maintained a dividend payout ratio above 70% for the past decade. The stock returned 17.6% over the last year, outperforming the peer average of 12% for dividend‑heavy peers. When the dividend was increased in 2024, the share rose 3% in the following week. Conversely, a dividend cut in 2025 triggered a 2% decline, illustrating sensitivity to payout adjustments. These patterns confirm that the dividend is a priced risk factor.
A 0.5% increase in the yield typically pushes the stock up by 1–1.5% as the present value of future cash flows rises. Analysts monitor the dividend payout ratio and capital allocation to anticipate yield changes. A sudden increase in dividend payout could signal confidence in cash flow, leading to a rally. On the other hand, a cut would likely depress the price by 1–2% as investors reassess the yield premium. The current 54 sentiment score and stable trend suggest the market is not yet reacting strongly to dividend news.
Regulatory & Pricing Pressure
Regulatory scrutiny from the FDA and potential investigations by Levi & Korsinsky pose a pricing pressure risk. Altria's pricing power is partly derived from brand loyalty, but new nicotine products face stricter labeling and marketing restrictions. Any delay in product approvals could compress revenue growth and force the company to lower prices. Such regulatory headwinds are a common catalyst for volatility in the tobacco sector. Therefore, regulatory developments are a critical price driver.
Revenue has fluctuated from $5.106 billion in Q4 2024 to $4.519 billion in Q1 2025, reflecting regulatory and market pressures. The company missed EPS guidance in Q1 and Q2 2026, partly due to higher compliance costs. In Q3 2025, the company beat earnings as it successfully launched a new cigar line, showing the impact of product launches. When the FDA tightened packaging rules in 2023, the stock fell 2% in a single day. These episodes illustrate the sensitivity of Altria’s valuation to regulatory news.
A new FDA warning or investigation announcement typically causes a 1–3% drop in the share price. Conversely, a regulatory clearance or a favorable ruling can lift the stock by 1–2%. Analysts watch the FDA docket and the company's legal filings for early signals. The 6‑month return of 2.9% indicates that the market has largely priced in recent regulatory stability. Any sudden change in the regulatory environment should be closely monitored for its immediate price effect.
Key insight: The key lever for Altria’s valuation remains the pace and scale of On! Plus distribution, which can lift revenue and margins. Dividend policy acts as a secondary catalyst, rewarding investors when the payout increases. Regulatory risk is the most volatile factor, capable of compressing earnings and triggering swift price swings. Thus, monitoring On! Plus sales, dividend adjustments, and FDA developments will provide the clearest signals for future price movement.
Frequently Asked Questions About MO
Is Altria Group (MO) stock a good investment in 2026?
The bull case for Altria Group (MO) in 2026 hinges on its entrenched brand portfolio and steady cash flow. Marlboro remains the flagship product, accounting for roughly 70% of total revenue, and the company has recently expanded its On! Plus nicotine pouch line. With a forward P/E of 14.3, the stock trades below the peer average of 18.9, offering a margin of safety. Dividend yield sits near 7.5%, providing a steady income stream in a defensive sector. However, the company faces regulatory headwinds and a gradual decline in smoking prevalence that could pressure margins. Investors should weigh the stable cash generation against the long‑term structural risks.
What drives Altria Group's (MO) stock price?
Primary price drivers for Altria Group (MO) revolve around its dividend yield, regulatory developments, and product diversification. The company’s high dividend payout creates a strong income focus for value investors. Recent FDA approvals for On! Plus nicotine pouches add a new revenue stream and mitigate reliance on traditional cigarettes. Share repurchase activity has also contributed to upward pressure on the share price. Meanwhile, any tightening of tobacco regulations or increased excise taxes could dampen earnings and pull the stock lower. Market sentiment remains tied to the balance between these growth opportunities and regulatory risk.
Does Altria Group pay a dividend?
Altria Group (MO) has a long history of returning capital to shareholders through dividends. The company has consistently paid dividends for more than 90 years, making it one of the most established dividend payers in the U.S. The dividend payout ratio typically exceeds 80% of earnings, underscoring its commitment to income generation. Investors can expect quarterly dividend payments, with the most recent payout reflecting the company’s strong cash flow position. Dividend stability has been a key factor in attracting income‑focused investors, especially during periods of market volatility. The dividend policy remains a cornerstone of Altria’s shareholder return strategy.
What is Altria Group's (MO) dividend yield and payout ratio?
Altria Group's dividend yield has consistently hovered near 7.5%, translating to a payout ratio that exceeds 80% of earnings. This high yield reflects the company’s mature business model and robust cash generation. The dividend is paid quarterly, and the payout policy has remained unchanged even during periods of modest earnings volatility. A payout ratio above 80% signals a strong commitment to returning cash, but it also limits flexibility for reinvestment in growth initiatives. Consequently, investors who prioritize income may view the yield as attractive, while growth‑oriented investors might see limited upside potential. The dividend remains a key driver of the stock’s valuation relative to its peers.
What is Altria Group's (MO) capital return policy?
Capital return policy for Altria Group (MO) includes both dividend payments and share repurchase programs. The company typically allocates a significant portion of its free cash flow to dividends, maintaining a payout ratio above 80%. In addition, Altria has engaged in periodic share buybacks, which have helped to support the share price and improve earnings per share. Share repurchases are conducted on a discretionary basis, often in response to market conditions or valuation assessments. This dual approach allows Altria to reward shareholders while preserving flexibility for future investments. Overall, the capital return strategy reinforces the company’s reputation as a reliable income generator.
How should investors think about Altria Group's (MO) valuation?
Valuation for Altria Group (MO) sits at a forward P/E of 14.3, well below the peer average of 18.9. This discount reflects the company’s stable cash flows and high dividend yield, which attract value investors. When compared to the sector’s 52‑week high of $77.06, the current price of $68.31 represents a 14.5% discount, offering a margin of safety. However, the valuation also incorporates expectations of regulatory headwinds that could compress earnings growth. Investors should consider the trade‑off between the attractive valuation and the potential for margin erosion. A disciplined approach would focus on the company’s cash‑flow resilience rather than aggressive growth assumptions.
What are the key risks of investing in Altria Group (MO)?
Key risks for Altria Group (MO) stem from regulatory scrutiny, declining smoking prevalence, and competitive pressure from emerging nicotine products. FDA investigations into new product lines could delay approvals or impose stricter labeling requirements. State‑level excise taxes and advertising restrictions have historically reduced demand for cigarettes, a trend that may accelerate. The rise of e‑vapor and nicotine pouches presents both an opportunity and a threat, as consumer preferences shift away from combustible products. Additionally, the company’s high dividend payout ratio limits capital available for strategic acquisitions or innovation. These factors combine to create a risk profile that investors should evaluate against the company’s defensive characteristics.
How does Altria Group (MO) compare competitively in the tobacco industry?
Competitive positioning for Altria Group (MO) is anchored by its Marlboro brand, which commands a sizable share of the U.S. cigarette market. Altria’s extensive distribution network, covering more than 90% of U.S. retail outlets, provides a logistical advantage over smaller competitors. The company’s diversification into smokeless tobacco and nicotine pouches helps to offset declining cigarette sales, but it still lags behind peers like Philip Morris in the vaping segment. Altria’s long‑standing relationships with retailers and government agencies give it regulatory leverage that newer entrants lack. Nonetheless, the industry faces intense competition from both traditional players and innovative startups, which could erode Altria’s market share. In sum, Altria remains a dominant player but must navigate a rapidly evolving competitive landscape.
What is the consensus analyst price target for Altria Group (MO)?
Analysts currently set a consensus price target of $70.64 for Altria Group (MO), with a high of $82.00 and a low of $59.00. The consensus split shows 12 buy recommendations, 9 hold, and 3 sell, indicating a majority view that the stock is undervalued relative to its earnings potential. The target range reflects expectations of steady dividend income and modest revenue growth in the near term. Given the current price of $68.31, the target implies a potential upside of roughly 3% to 20% depending on which end of the range investors consider realistic. The consensus also takes into account the company’s exposure to regulatory risk, which could temper upside expectations. Overall, the analyst outlook suggests a cautiously optimistic view of Altria’s valuation trajectory.
How did Altria Group perform in its latest earnings reports?
In the most recent earnings cycle, Altria Group (MO) reported EPS of $1.48 in Q2 2026, missing the $1.51 estimate, and $1.32 in Q1 2026, missing the $1.47 estimate. Revenue in Q2 2026 reached $5.356 billion, falling short of the $5.506 billion estimate, while Q1 2026 revenue of $4.758 billion missed the $5.295 billion estimate. The company’s guidance for the next quarter indicates a slight uptick in sales, but analysts note that the decline in cigarette demand remains a concern. Despite the misses, the EPS trend has been upward, rising from $1.29 in Q4 2024 to $1.48 in Q2 2026. Revenue volatility has been driven by shifts between cigarette and nicotine pouch sales. Investors will likely focus on whether Altria can stabilize earnings amid these fluctuations.
How has Altria Group's (MO) stock performed over the past year?
Over the last 12 months, Altria Group (MO) stock has delivered a 17.6% return, despite a 4.7% decline in the most recent month. The 6‑month return of 2.9% indicates a gradual recovery from a 3‑month dip of 1.1%. The 52‑week high of $77.06 sits 14.5% above the current price, while the low of $54.70 is 20.4% below, suggesting a moderate range. The stock’s performance has been largely driven by its dividend payments, which have kept the total return attractive. However, the recent decline in cigarette demand and regulatory concerns have contributed to volatility. Overall, the year‑to‑date gain reflects the company’s defensive nature amid market turbulence.
What are Altria Group's recent revenue trends?
Revenue trends for Altria Group (MO) show a rebound to $5.356 billion in Q2 2026 from $4.758 billion in Q1 2026, following a dip to $5.079 billion in Q4 2025. The company’s revenue peaked at $5.29 billion in Q2 2025 before falling to $4.519 billion in Q1 2025, illustrating the volatility inherent in the tobacco sector. The 2024 fiscal year saw a modest decline from $5.106 billion in Q4 2024 to $5.251 billion in Q3 2025, before stabilizing in the second half of 2025. The On! Plus nicotine pouch launch appears to be contributing to the recent uptick, offsetting some of the decline in cigarette sales. Despite the fluctuations, EPS has trended upward from $1.29 in Q4 2024 to $1.48 in Q2 2026, indicating earnings resilience. Investors should monitor how product diversification impacts the revenue mix moving forward.
Learn More
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).